160 related articles for article (PubMed ID: 22243773)
1. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma.
Duffaud F; Egerer G; Ferrari S; Rassam H; Boecker U; Bui-Nguyen B
Eur J Cancer; 2012 Mar; 48(4):564-70. PubMed ID: 22243773
[TBL] [Abstract][Full Text] [Related]
2. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
Chen JS; Chao Y; Bang YJ; Roca E; Chung HC; Palazzo F; Kim YH; Myrand SP; Mullaney BP; Shen LJ; Linn C
Anticancer Drugs; 2010 Sep; 21(8):777-84. PubMed ID: 20634689
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
Lee HY; Ahn MJ; Park YH; Ahn JS; Kim BS; Kim HK; Kim HT; Ryoo HM; Bae SH; Lee SS; Choi K; Hong DS; Lee KH; Kwon JH; Choi IS; Kim BS; Lee NS; Gong SJ; Park K
Lung Cancer; 2009 Dec; 66(3):338-43. PubMed ID: 19299031
[TBL] [Abstract][Full Text] [Related]
14. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study.
John W; Picus J; Blanke CD; Clark JW; Schulman LN; Rowinsky EK; Thornton DE; Loehrer PJ
Cancer; 2000 Apr; 88(8):1807-13. PubMed ID: 10760756
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.
Gilbert J; Murphy B; Dietrich MS; Henry E; Jordan R; Counsell A; Wirth P; Yarbrough WG; Slebos RJ; Chung CH
Cancer; 2012 Feb; 118(4):1007-13. PubMed ID: 21766301
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.
Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G
Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.
Martin M; Blasinska-Morawiec M; Salas JF; Falcon S; Rolski J; Ferrari BL; Gulyas S; Liu Y; Benhadji KA
Clin Breast Cancer; 2009 Aug; 9(3):155-60. PubMed ID: 19661038
[TBL] [Abstract][Full Text] [Related]
19. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.
Kim YH; Chung HC; Kang WK; Park SR; Kim CS; Kim TY; Shin SW; Park BJ; Cha SJ; Bang YJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):263-70. PubMed ID: 17960386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
